Compare Amgen, Inc. (AMGN) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs JetBlue Airways Corporation — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while JetBlue Airways Corporation trades at $5.72 (market cap $2.14B). The key difference: Amgen, Inc. is far larger — about 91.6× JetBlue Airways Corporation's market cap, and Amgen, Inc. pays a 2.77% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals.
| AMGN | JBLU | |
|---|---|---|
Market Cap | $196.12B | $2.14B |
Sector | Health | Industrials |
52-Week High | $388.16 | $6.46 |
52-Week Low | $271.18 | $4.03 |
Enterprise Value | $241.41B | $9.31B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
JetBlue (JBLU) trades at $5.76, down 2.7% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported a net loss of $602 million in 2025, with negative profit margins and elevated debt levels. Recent news highlights a major Fort Lauderdale expansion, while analyst consensus is predominantly Hold with a $5.12 price target below the current price.
The outlook remains challenging due to persistent losses and high leverage, though expansion efforts and potential fuel cost relief offer some upside. Key risks include volatile oil prices, competitive pressure, and execution of the turnaround strategy. Investors should weigh cost management improvements against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
